Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

AXSM

Phase 3

Solriamfetol

Shift work disorder

2026

SUSTAIN: 8/5/24- Initiates trial, topline results in 2026.

Data readout

HRMY

Phase 2

EPX-100 [clemizole hydrochloride]

Dravet syndrome (DS)

2026

ARGUS trial. 4/30/24 Asset from Epygenix Therapeutics acquisition. Topline data in 2026. Initiate Ph3 trials for LGS later this year.

Data readout

ANNX

Phase 3

ANX007 (IVT)

GA (Geographic Atrophy)

H2 2026

ARCHER, ARCHER II, & ARROW trials. Presented add'l data at ARVO '24 and ASRS '24. 8/5/24- Dosed in Ph3 trial. 10/17/24- New Ph2 ARCHER data at AAO '24. 12/5/24- Presented Ph2 data at Floretina-ICOOR '24. Ph3 ARCHER II actively enrolling with topline data in H2 2026.

Data readout

ALLO

Phase 2

Cemacabtagene Ansegedleucel (cema-cel)

Large B cell lymphoma (LBCL)

YE 2026

ALPHA3 trial. 6/20/24- Trial initiated. 7/1/24- Complete enrollment in H1 2026; Interim Efficacy analysis by DSMB in H1 '26 & readout in YE '26. BLA Submission in 2027

Data readout

OLMA

Phase 3

OP-1250 (palazestrant) (CER antagonist)

ER+ HER2- MBC (Metastatic Breast Cancer)

2026

OPERA-1 trial. 12/5/23 Trial-in-progress poster presentation at SABCS '23. Clinical sites activated, enrolling w/ first patient dosed in Nov 2023. Trial-in-progress poster at ASCO '24. Topline data in 2026.

Data readout

ZNTL

Phase 2

Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono

Cyclin E1+ platinum-resistant ovarian cancer (PROC)

YE 2026

DENALI (ZN-c3-005): 1/29/25- Reported topline data from Part 1b. 3/15/25- Presented updated data at (SGO) 2025. Initiate Part 2 in H1 2025 with topline data by YE 2026.

Data readout

IONS

Phase 3

Ulefnersen (ION363 )

FUS-ALS (Amyotrophic Lateral Sclerosis)

2026

Phase 3 trial was initiated in first half of 2021. Data in 2026

Data readout

MIRM

Phase 2b

Volixibat

PSC (Primary Sclerosing Cholangitis)

2026

VISTAS trial. 6/17/24- Reported interim analyses data. Q4 2024- Complete enrollment in H2 2025; topline data in 2026.

Update

IONS

Phase 3

Eplontersen (AKCEA-TTR-LRx)

ATTR cardiomyopathy (ATTR-CM)

2026

CARDIO-TTRansform. Partnered with AstraZeneca. Phase 3 full enrollment 7/31/2023, data in 2026.

Data readout

MNMD

Phase 3

MM120 (lysergide D-tartrate)

Major Depressive Disorder (MDD)

H2 2026

Emerge Study (MM120-310): 8/13/24 Initiate Ph3 program w/ Part A & Part B in H1 2025 w/ Part A topline data in H2 2026.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20